drugset / Trial / NCT01067443

Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa

NCT01067443

RandomizedParallel-groupOpen-labelTreatment

Summary

This study is to assess if shorter combinations of SSG plus single dose AmBisome®, Miltefosine plus single dose AmBisome® and Miltefosine alone are effective in treating visceral leishmaniasis in Eastern Africa.

Timeline

Start
2010-03
Primary completion
2011-06
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Amphotericin B Unknown 10 mg/kg Intravenous
Subject Miltefosine Small molecule 2.5 mg/kg Oral
Subject sodium stibogluconate Unknown 20 mg/kg Intravenous